Healio Rapid Response From Angiogenesis 2025: Advances in Treating Diabetic Macular Edema
The therapeutic landscape for diabetic macular edema (DME) is rapidly evolving with the introduction of novel treatments, protocols, and delivery methods designed to improve visual outcomes and reduce patient burden. Advancements include extended injection protocols that are the result of longer durations of action for recently approved therapies and the Port Delivery System with ranibizumab—a sustained drug delivery system that was approved in February of 2025 for the treatment of patients with DME. In this Rapid Response activity, experts in the field discuss the latest clinical reports on the treatment of DME as presented at the Angiogenesis 2025 meeting. Faculty engage in a fast-paced review of the latest data on DME treatments, protocols, and modalities and discuss how these updates affect their own clinical practices and the broader field of retinal care.
Details
The therapeutic landscape for diabetic macular edema (DME) is rapidly evolving with the introduction of novel treatments, protocols, and delivery methods designed to improve visual outcomes and reduce patient burden. Advancements include extended injection protocols that are the result of longer durations of action for recently approved therapies and the Port Delivery System with ranibizumab—a sustained drug delivery system that was approved in February of 2025 for the treatment of patients with DME. In this Rapid Response activity, experts in the field discuss the latest clinical reports on the treatment of DME as presented at the Angiogenesis 2025 meeting. Faculty engage in a fast-paced review of the latest data on DME treatments, protocols, and modalities and discuss how these updates affect their own clinical practices and the broader field of retinal care.
Topics Covered
Advances in Treating Diabetic Macular Edema
Learning Objectives
Upon successful completion of this activity, participants should be better able to analyze the latest clinical data on advancements in the medical management of patients with DME.
Target Audience
Ophthalmologists and retina specialists involved in the management of patients with DME.
Additional credit info
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, March 14, 2025, to March 13, 2026.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.